Katherine A. High

2018

In 2018, Katherine A. High earned a total compensation of $2.3M as President and Head of Research and Development at Spark Therapeutics, a 8% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$233,179
Option Awards$1,086,725
Salary$471,039
Stock Awards$454,950
Other$39,058
Total$2,284,951

High received $1.1M in option awards, accounting for 48% of the total pay in 2018.

High also received $233.2K in non-equity incentive plan, $471K in salary, $455K in stock awards and $39.1K in other compensation.

Rankings

In 2018, Katherine A. High's compensation ranked 5,051st out of 14,244 executives tracked by ExecPay. In other words, High earned more than 64.5% of executives.

ClassificationRankingPercentile
All
5,051
out of 14,244
65th
Division
Manufacturing
1,899
out of 5,759
67th
Major group
Chemicals And Allied Products
695
out of 2,122
67th
Industry group
Drugs
581
out of 1,811
68th
Industry
Biological Products, Except Diagnostic Substances
118
out of 339
65th

Pay ratio

Katherine A. High's Pay$2,284,951
Median Employee's Pay$182,200
Pay Ratio

13

to 1

In 2018, the annual total compensation of Katherine A. High was $2,284,951.

The annual total compensation of the median employee at Spark Therapeutics was $182,200.

The ratio of Katherine A. High's pay to the pay of median employee was therefore 13 to one.

Source: SEC filing on July 22, 2019.

High's colleagues

We found four more compensation records of executives who worked with Katherine A. High at Spark Therapeutics in 2018.

2018

Jeffrey Marrazzo

Spark Therapeutics

Chief Executive Officer

2018

John Furey

Spark Therapeutics

Chief Operating Officer

2018

Daniel Faga

Spark Therapeutics

Chief Business Officer

2018

Stephen Webster

Spark Therapeutics

Chief Financial Officer

News

You may also like